RUTHERFORD, N.J., May 29, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today the presentation of results from a research collaboration with Memorial Sloan Kettering Cancer Center at the 2015 American Society of Clinical Oncology Annual Meeting, taking place at the McCormick Place Convention Center in Chicago, Illinois on May 29-June 2, 2015. The findings of the study, led Dr. Robert Motzer, MD at Memorial Sloan Kettering Cancer Center and Dr. Jane Houldsworth, PhD at CGI, showcase that novel copy number alterations detected by whole genome comparative genomic hybridization may provide insight into sunitinib resistance in patients with advanced renal cell carcinoma.
Details for the poster presentation are the following:
|Session:||Genitourinary (Nonprostate) Cancer|
|Date and Time:||Monday, June 1st, 2015 1:15PM to 4:45PM CT|
|Location:||S Hall A|
|Poster #225: "Novel chromosome copy changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma"|
Cancer Genetics will be exhibiting in booth 21141.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow us:
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Media Relations Marie Michellod Cancer Genetics, Inc. 201-776-1983 Media@cgix.com
Source:Cancer Genetics, Inc.